Program
inobrodib
Also written as “CCS1477”, “Inobrodib” and “InoPd”.
Its studies are mostly in Multiple Myeloma · Breast Neoplasms · Hematologic Neoplasms, led by CellCentric.
Furthest: phase 3, since Aug 13, 20264 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CellCentric | 43 open or running | phase 3since Aug 13, 2026 | Jun 4, 2018 | Mar 31, 2027phase 2 · NCT04068597 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 4, 2018First study: phase 2 study in Breast NeoplasmsFirst studyNCT03568656 · 219 enrolled · United States, France, Netherlands and more
- Aug 12, 2019Phase 2 study in Hematologic NeoplasmsNCT04068597 · 250 planned · United States, France, Spain and more
- Jul 24, 2025Phase 2 study in Multiple Myeloma RefractoryNCT07096778 · 100 planned · United States, United Kingdom
- Aug 13, 2026Phase 3 study in Multiple Myeloma RefractoryPhase 3 reachedNCT07772024 · 450 planned · United States
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT04068597
- Nov 2029Primary completion: phase 3 study in Multiple Myeloma RefractoryNCT07772024
- Dec 1, 2029Primary completion: phase 2 study in Multiple Myeloma RefractoryNCT07096778
TargetBeta
OPN1LW →read by rule
“An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), ”NCIt, by rule
Other programs on OPN1LW
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pocenbrodibrule | pathos-ai-inc | phase 2 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07772024Multiple Myeloma Refractory · United States | 3 | Recruiting | Nov 2029 | 450 |
| NCT07096778Multiple Myeloma Refractory · United States, United Kingdom | 2 | Recruiting | Dec 1, 2029 | 100 |
| NCT04068597Hematologic Neoplasms · United States, France, Spain and more | 2 | Recruiting | Mar 31, 2027 | 250 |
| NCT03568656Breast Neoplasms · United States, France, Netherlands and more | 2 | Completed | Jul 6, 2025 | 219 |
How it is read
Names in the registry
- “CCS1477”, 2 entries
- “Inobrodib”, 1 entry
- “InoPd”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
- Breast Neoplasms, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.